Nuformix plc (LON:NFX – Get Free Report) shares reached a new 52-week low on Tuesday. The stock traded as low as GBX 0.06 and last traded at GBX 0.07, with a volume of 111,689,094 shares changing hands. The stock had previously closed at GBX 0.07.
Nuformix Stock Down 13.3%
The company has a market cap of £1.70 million, a P/E ratio of -2.22 and a beta of 1.53. The business has a fifty day simple moving average of GBX 0.12 and a two-hundred day simple moving average of GBX 0.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
